Belite Bio, a subsidiary of Lin Bioscience focused on targeting untreatable age-related metabolic diseases, announced that the U.S. FDA approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967) for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease. LBS-008 will be one of the first drugs to graduate from the US National Institute of Health's (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which has funded LBS-008's discovery and development, and will continue to provide support and funding until the completion of its Phase 1 single ascending dose (SAD) clinical trial.
A phase 1 study commenced in Australia in October 2018 and is expected to complete this study during the 2nd half of 2019.
About Atrophic Age-related Macular Degeneration and Stargardt Disease
Dry Age-Related Macular Degeneration (AMD) and Stargardt Disease are untreatable conditions that cause vision loss in adults and children, respectively.
Age-related Macular Degeneration (AMD) is a disease that can cause irreversible loss of central vision, which is used for seeing fine details during activities such as re...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).